Intriguingly, a follow-up study with cambinol-based dual SIRT1/2 inhibitors demonstrated a strong correlation between SIRT2 inhibitory activity and cytotoxicity in Namalwa Burkitt lymphoma cell line [40]. The gene discussed is SIRT2; the disease is Burkitt lymphoma.